On August 3, AstraZeneca PLC fell 6.12% in pre-market trading, trading at $159.17/share, hitting its lowest level since October of the prior year.

On the news front, AstraZeneca PLC is reportedly in discussions with Bristol-Myers Squibb over a potential merger that could value the combined entity at approximately $400 billion, potentially making it one of the largest pharmaceutical transactions in history. AstraZeneca PLC currently carries a market capitalization of approximately $264 billion, while Bristol-Myers Squibb is valued at roughly $133 billion. Negotiations have reportedly been ongoing for several months but remain subject to significant uncertainty.

The deal reflects broader industry efforts by major drugmakers to expand innovative pipelines through M&A amid patent expiration pressures. Bristol-Myers Squibb faces looming patent cliffs on core products Eliquis and Opdivo, which together account for roughly half of its revenue. Market participants are expressing concern over potential acquisition premiums and integration risks, weighing heavily on AstraZeneca PLC shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)